| Members |
acceptabilityId |
| 67 |
Preferred (foundation metadata concept) |
| 67 (qualifier value) |
Preferred (foundation metadata concept) |
| 67-Cu |
Acceptable (foundation metadata concept) |
| 67-Ga |
Acceptable (foundation metadata concept) |
| 670 |
Preferred (foundation metadata concept) |
| 670 (qualifier value) |
Preferred (foundation metadata concept) |
| 6712 |
Preferred (foundation metadata concept) |
| 675 |
Preferred (foundation metadata concept) |
| 675 (qualifier value) |
Preferred (foundation metadata concept) |
| 68 |
Preferred (foundation metadata concept) |
| 68 (qualifier value) |
Preferred (foundation metadata concept) |
| 68-Ga |
Acceptable (foundation metadata concept) |
| 68-Ge |
Acceptable (foundation metadata concept) |
| 68.6 |
Preferred (foundation metadata concept) |
| 68.6 (qualifier value) |
Preferred (foundation metadata concept) |
| 686 |
Preferred (foundation metadata concept) |
| 686 (qualifier value) |
Preferred (foundation metadata concept) |
| 69 |
Preferred (foundation metadata concept) |
| 69 (qualifier value) |
Preferred (foundation metadata concept) |
| 69-Ge |
Acceptable (foundation metadata concept) |
| 69-Zn |
Acceptable (foundation metadata concept) |
| 69m-Zn |
Acceptable (foundation metadata concept) |
| 6Fr |
Acceptable (foundation metadata concept) |
| 6MP |
Acceptable (foundation metadata concept) |
| 6MWT (6 minute walk test) distance |
Acceptable (foundation metadata concept) |
| 6MWT - 6 minute walk test |
Acceptable (foundation metadata concept) |
| 6PPH4(2'-oxo) reductase |
Acceptable (foundation metadata concept) |
| 6PTS - 6-Pyruvoyl-tetrahydrobiopterin synthase deficiency |
Acceptable (foundation metadata concept) |
| 6g protein exchanges/day |
Preferred (foundation metadata concept) |
| 6g protein exchanges/day (qualifier value) |
Preferred (foundation metadata concept) |
| 6g protein exchanges/kg body weight |
Preferred (foundation metadata concept) |
| 6g protein exchanges/kg body weight (qualifier value) |
Preferred (foundation metadata concept) |
| 6g protein exchanges/meal |
Preferred (foundation metadata concept) |
| 6g protein exchanges/meal (qualifier value) |
Preferred (foundation metadata concept) |
| 6p partial trisomy syndrome |
Preferred (foundation metadata concept) |
| 6p partial trisomy syndrome (disorder) |
Preferred (foundation metadata concept) |
| 6p22 microdeletion syndrome |
Preferred (foundation metadata concept) |
| 6p22 microdeletion syndrome (disorder) |
Preferred (foundation metadata concept) |
| 6p22 microdeletion syndrome is a newly described syndrome associated with a variable clinical phenotype including developmental delay, facial dysmorphism, short neck and diverse malformations. |
Preferred (foundation metadata concept) |
| 6q partial trisomy syndrome |
Preferred (foundation metadata concept) |
| 6q partial trisomy syndrome (disorder) |
Preferred (foundation metadata concept) |
| 6q terminal deletion syndrome |
Preferred (foundation metadata concept) |
| 6q terminal deletion syndrome (disorder) |
Preferred (foundation metadata concept) |
| 6q16 microdeletion syndrome |
Preferred (foundation metadata concept) |
| 6q16 microdeletion syndrome (disorder) |
Preferred (foundation metadata concept) |
| 6q25 microdeletion syndrome |
Preferred (foundation metadata concept) |
| 6q25 microdeletion syndrome (disorder) |
Preferred (foundation metadata concept) |
| 6q25 microdeletion syndrome is a recently described syndrome characterised by developmental delay, facial dysmorphism and hearing loss. |
Preferred (foundation metadata concept) |
| 6th floor |
Acceptable (foundation metadata concept) |
| 6th nerve palsy |
Acceptable (foundation metadata concept) |
| 6th nerve palsy |
Acceptable (foundation metadata concept) |
| 6x/wk |
Acceptable (foundation metadata concept) |
| 7 |
Preferred (foundation metadata concept) |
| 7 |
Preferred (foundation metadata concept) |
| 7 (qualifier value) |
Preferred (foundation metadata concept) |
| 7 French gauge |
Preferred (foundation metadata concept) |
| 7 French gauge (qualifier value) |
Preferred (foundation metadata concept) |
| 7 day ambulatory ECG (electrocardiographic) monitoring |
Acceptable (foundation metadata concept) |
| 7 day ambulatory electrocardiographic monitoring |
Preferred (foundation metadata concept) |
| 7 day ambulatory electrocardiographic monitoring (procedure) |
Preferred (foundation metadata concept) |
| 7 dehydrocholesterol |
Preferred (foundation metadata concept) |
| 7 dehydrocholesterol (substance) |
Preferred (foundation metadata concept) |
| 7 mm caliber bullet, device |
Acceptable (foundation metadata concept) |
| 7 mm caliber bullet, device (physical object) |
Preferred (foundation metadata concept) |
| 7 mm calibre bullet |
Preferred (foundation metadata concept) |
| 7 nm filaments |
Preferred (foundation metadata concept) |
| 7 nm filaments (cell structure) |
Preferred (foundation metadata concept) |
| 7 o'clock position |
Preferred (foundation metadata concept) |
| 7 o'clock position (qualifier value) |
Preferred (foundation metadata concept) |
| 7 o'clock position on mammogram |
Preferred (foundation metadata concept) |
| 7 o'clock position on mammogram (finding) |
Preferred (foundation metadata concept) |
| 7,8-Dihydrobiopterin synthetase deficiency |
Acceptable (foundation metadata concept) |
| 7,8-diaminononanoate aminotransferase |
Acceptable (foundation metadata concept) |
| 7,8-dihydroxykynurenate 8,8a-dioxygenase |
Preferred (foundation metadata concept) |
| 7,8-dihydroxykynurenate 8,8a-dioxygenase (substance) |
Preferred (foundation metadata concept) |
| 7,8-dihydroxykynurenate oxygenase |
Acceptable (foundation metadata concept) |
| 7-Aminoflunitrazepam measurement |
Preferred (foundation metadata concept) |
| 7-Aminoflunitrazepam measurement (procedure) |
Preferred (foundation metadata concept) |
| 7-Be |
Acceptable (foundation metadata concept) |
| 7-Dehydrocholesterol level |
Preferred (foundation metadata concept) |
| 7-Dehydrocholesterol measurement |
Acceptable (foundation metadata concept) |
| 7-Dehydrocholesterol measurement (procedure) |
Preferred (foundation metadata concept) |
| 7-Dehydrocholesterol reductase deficiency |
Acceptable (foundation metadata concept) |
| 7-WAY CLOSTRIDIUM |
Preferred (foundation metadata concept) |
| 7-WAY CLOSTRIDIUM (product) |
Preferred (foundation metadata concept) |
| 7-aminoflunitrazepam |
Preferred (foundation metadata concept) |
| 7-aminoflunitrazepam (substance) |
Preferred (foundation metadata concept) |
| 7-bromo-5-methyl-8-quinolinol |
Acceptable (foundation metadata concept) |
| 7-dehydrocholesterol |
Acceptable (foundation metadata concept) |
| 7-dehydrocholesterol reductase |
Preferred (foundation metadata concept) |
| 7-dehydrocholesterol reductase (substance) |
Preferred (foundation metadata concept) |
| 7-hydroxymitragynine |
Preferred (foundation metadata concept) |
| 7-hydroxymitragynine (substance) |
Preferred (foundation metadata concept) |
| 7-hydroxyoctanoate |
Preferred (foundation metadata concept) |
| 7-hydroxyoctanoate (substance) |
Preferred (foundation metadata concept) |
| 7.08 |
Preferred (foundation metadata concept) |
| 7.08 (qualifier value) |
Preferred (foundation metadata concept) |
| 7.083 |
Preferred (foundation metadata concept) |
| 7.083 (qualifier value) |
Preferred (foundation metadata concept) |
| 7.2 |
Preferred (foundation metadata concept) |
| 7.2 (qualifier value) |
Preferred (foundation metadata concept) |
FHIR